Kitamura Yuki, Usami Ryoko, Ichihara Sahoko, Kida Hirotaka, Satoh Masayuki, Tomimoto Hidekazu, Murata Mariko, Oikawa Shinji
a Department of Environmental and Molecular Medicine , Mie University Graduate School of Medicine , Tsu , Japan.
b Graduate School of Regional Innovation Studies , Mie University , Tsu , Japan.
Neurol Res. 2017 Mar;39(3):231-238. doi: 10.1080/01616412.2017.1281195. Epub 2017 Jan 20.
Alzheimer's disease (AD) is the most common cause of dementia in elderly persons. Since the pathology of AD develops slowly from a preclinical or early phase into a fully expressed clinical syndrome, at the time of diagnosis the disease has been progressing for many years. To facilitate the early diagnosis of AD, we performed protein profiling of blood in patients with mild AD as defined by the Functional Assessment Staging (FAST) scale.
Plasma samples from mild AD patients and healthy controls were analyzed using two-dimensional differential gel electrophoresis (2D-DIGE) combined with matrix-assisted laser desorption ionization time-of-flight tandem mass spectrometry (MALDI-TOF/TOF/MS) followed by peptide mass fingerprinting.
Three downregulated proteins were identified: apolipoprotein A-1, alpha-2-HS-glycoprotein, and afamin. Two proteins, including apolipoprotein A-4 and fibrinogen gamma chain, were upregulated in mild AD patients.
Our results suggest that altered expression levels of these proteins in plasma may yield candidate biomarkers for the early diagnosis of AD.
AD, Alzheimer's disease; FAST, Functional Assessment Staging; 2D-DIGE, two-dimensional differential gel electrophoresis; MALDI-TOF/TOF/MS, matrix-assisted laser desorption ionization time-of-flight tandem mass spectrometry; CSF, cerebrospinal fluid; Aβ, amyloid beta; MMSE, Mini Mental State Examination; MRI, magnetic resonance imaging; NINCDS-ADRDA, National Institute for Neurological Diseases and Stroke/Alzheimer's Disease and Related Disorders Association; CHAPS, 3-((3-cholamidopropyl) dimethylammonio)-1-propanesulfonate; DTT, dithiothreitol; SDS-PAGE, SDS-polyacrylamide gel electrophoresis; DIA, differential in-gel analysis; BVA, biological variation analysis; CBB, Coomassie brilliant blue; 2DE, two-dimensional gel electrophoresis; TFA, trifluoroacetic acid; ACTH, adrenocorticotropic hormone; Apo A-1, apolipoprotein A-1; AHSG, alpha-2-HS-glycoprotein; Apo A-4, apolipoprotein A-4; MCI, mild cognitive impairment.
阿尔茨海默病(AD)是老年人痴呆最常见的病因。由于AD的病理过程从临床前或早期阶段缓慢发展为完全显现的临床综合征,在诊断时该病已进展多年。为促进AD的早期诊断,我们对功能评估分期(FAST)量表定义的轻度AD患者的血液进行了蛋白质谱分析。
使用二维差异凝胶电泳(2D-DIGE)结合基质辅助激光解吸电离飞行时间串联质谱(MALDI-TOF/TOF/MS),随后进行肽质量指纹图谱分析,对轻度AD患者和健康对照的血浆样本进行分析。
鉴定出三种下调蛋白:载脂蛋白A-1、α-2-HS-糖蛋白和afamin。两种蛋白,包括载脂蛋白A-4和纤维蛋白原γ链,在轻度AD患者中上调。
我们的结果表明,这些血浆蛋白表达水平的改变可能产生AD早期诊断的候选生物标志物。
AD,阿尔茨海默病;FAST,功能评估分期;2D-DIGE,二维差异凝胶电泳;MALDI-TOF/TOF/MS,基质辅助激光解吸电离飞行时间串联质谱;CSF,脑脊液;Aβ,淀粉样β蛋白;MMSE,简易精神状态检查表;MRI,磁共振成像;NINCDS-ADRDA,美国国立神经疾病和中风研究所/阿尔茨海默病及相关疾病协会;CHAPS,3-((3-胆酰胺丙基)二甲基铵)-1-丙烷磺酸盐;DTT,二硫苏糖醇;SDS-PAGE,SDS-聚丙烯酰胺凝胶电泳;DIA,差异凝胶内分析;BVA,生物学变异分析;CBB,考马斯亮蓝;2DE,二维凝胶电泳;TFA,三氟乙酸;ACTH,促肾上腺皮质激素;Apo A-1,载脂蛋白A-1;AHSG,α-2-HS-糖蛋白;Apo A-4,载脂蛋白A-4;MCI,轻度认知障碍。